VolitionRx Limited has announced proof-of-concept data showing its Capture-Seq liquid biopsy technology achieved over 95% sensitivity for detecting stage I and II cancers with 95% specificity in a blinded validation cohort. The study included 81 subjects and demonstrated detection rates of 94% for stage I cancers and 96% for stage II cancers, with overall sensitivity of 93% and specificity of 95%.
The technology's performance in early-stage cancer detection represents a significant advancement in the field of liquid biopsies, which analyze circulating tumor DNA from blood samples. Capture-Seq is designed to enrich and purify circulating tumor DNA for analysis, potentially supporting applications in multi-cancer early detection and minimal residual disease monitoring. This non-invasive approach could transform cancer screening by providing accurate detection before symptoms appear, when treatment is most effective.
Volition noted the technology targets an estimated $36 billion total addressable market and is currently the subject of discussions with potential licensing and diagnostic partners to accelerate development and commercialization. The company's research and development activities are centered in Belgium, with additional facilities in the U.S. and London. For further information about the company's work in epigenetics and disease detection, visit https://volition.com/.
The implications of this technology extend beyond improved patient outcomes to potentially reducing healthcare costs through earlier intervention. Early cancer detection has been shown to significantly improve survival rates and reduce treatment complexity. If successfully commercialized, Capture-Seq could become a routine screening tool, similar to current blood tests, making regular cancer screening more accessible and less invasive than traditional methods like biopsies and imaging.
This announcement comes as the liquid biopsy market continues to expand, with increasing demand for non-invasive diagnostic tools. The detailed findings from the validation study are available in the full press release at https://ibn.fm/ktVDF. While these results are promising, further validation in larger, more diverse populations will be necessary before the technology can receive regulatory approval and enter widespread clinical use.
